Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far

2026-03-03 09:15:24 ET

Thesis

Arcus Biosciences ( RCUS ) managed to post a 4Q25 GAAP EPS of -$0.89, a figure that beat consensus estimates by about $0.14. We saw some better-than-expected cost control and decent collaboration revenue throughout the quarter. The company also posted a revenue figure of $33 million, down just 8.3% year over year but still beating expectations by $8.06 million. This was driven mainly by partnership-related payments. But overall, the quarter showed us pretty solid earnings and revenue beat despite Arcus still going through a heavy investment phase with no commercial products yet....

Read the full article on Seeking Alpha

For further details see: